Rezafungin <i>In Vitro</i> Activity against Contemporary Nordic Clinical <i>Candida</i> Isolates and <i>Candida auris</i> Determined by the EUCAST Reference Method
Marie Helleberg, Karin Meinike Jørgensen, Rasmus Krøger Hare, Raluca Datcu, Anuradha Chowdhary, Maiken Cavling Arendrup
Abstract
Rezafungin (formerly CD101) is a novel echinocandin in clinical development. EUCAST epidemiological cutoff values (ECOFFs) have not yet been established. We determined the in vitro activity of rezafungin and comparators against 1,293 Nordic yeast isolates and 122 Indian Candida auris isolates and established single-center wild-type upper limits (WT-UL). The isolates (19 Candida spp. and 13 other yeast species) were identified using Chromagar; matrix-assisted laser desorption ionization–time of flight (MALDI-TOF); and, when needed, internal transcribed spacer sequencing.
Topics & Concepts
Candida aurisMicrobiologyCandida infectionsIn vitroBiologyCandida albicansAntifungalBiochemistryAntifungal resistance and susceptibilityFungal Infections and StudiesInfectious Diseases and Mycology